{"id":"minoxidil-finasteride","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Scalp irritation or dermatitis (minoxidil)"},{"rate":"1-3","effect":"Sexual dysfunction or decreased libido (finasteride)"},{"rate":"1-3","effect":"Dizziness or lightheadedness (minoxidil)"},{"rate":"<1","effect":"Gynecomastia (finasteride)"},{"rate":"5-10","effect":"Hypertrichosis (minoxidil)"}]},"_chembl":{"chemblId":"CHEMBL802","moleculeType":"Small molecule","molecularWeight":"209.25"},"_dailymed":{"setId":"27697b1c-f713-f7e0-e063-6394a90a7514","title":"JOHNSON FOAM PRO (FINASTERIDE FOAM WITH 5% MINOXIDIL) AEROSOL, FOAM [JOHNSON BIOPHARMACEUTICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and extends the growth phase of the hair cycle. Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting 5-alpha reductase, reducing the androgenic signal that causes hair follicle miniaturization in male pattern baldness. Together, they address hair loss through complementary mechanisms.","oneSentence":"Minoxidil stimulates hair growth by prolonging the anagen phase and improving blood flow to hair follicles, while finasteride inhibits 5-alpha reductase to reduce DHT-mediated hair loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:30.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male pattern baldness)"},{"name":"Hair loss in men"}]},"trialDetails":[{"nctId":"NCT07435012","phase":"PHASE3","title":"Androgenic Alopecia TH07 Clinical Trial","status":"RECRUITING","sponsor":"Triple Hair Inc","startDate":"2026-04","conditions":"Androgenic Alopecia","enrollment":420},{"nctId":"NCT07076706","phase":"PHASE2","title":"Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","startDate":"2024-12-05","conditions":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","enrollment":110},{"nctId":"NCT04594018","phase":"PHASE3","title":"Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia","status":"RECRUITING","sponsor":"EMS","startDate":"2023-02-02","conditions":"Androgenetic Alopecia","enrollment":190},{"nctId":"NCT07038941","phase":"PHASE1","title":"Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","startDate":"2024-03-19","conditions":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","enrollment":44},{"nctId":"NCT06826001","phase":"PHASE2","title":"Various Procedural Treatment Options for Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2025-02","conditions":"Androgenetic Alopecia","enrollment":190},{"nctId":"NCT05990400","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-05-01","conditions":"Androgenetic Alopecia","enrollment":40},{"nctId":"NCT02824380","phase":"PHASE1","title":"Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-07","conditions":"Androgenic Alopecia","enrollment":14},{"nctId":"NCT02483195","phase":"PHASE4","title":"The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2016-08","conditions":"Female Androgenetic Alopecia","enrollment":""},{"nctId":"NCT01643629","phase":"PHASE1, PHASE2","title":"A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Kasiak Research Pvt. Ltd.","startDate":"2012-01","conditions":"Androgenetic Alopecia","enrollment":20},{"nctId":"NCT01391156","phase":"PHASE3","title":"Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss","status":"COMPLETED","sponsor":"Mae Fah Luang University Hospital","startDate":"2011-03","conditions":"Androgenetic Alopecia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"minoxidil + finasteride","genericName":"minoxidil + finasteride","companyName":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","companyId":"beijing-dayspring-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minoxidil stimulates hair growth by prolonging the anagen phase and improving blood flow to hair follicles, while finasteride inhibits 5-alpha reductase to reduce DHT-mediated hair loss. Used for Androgenetic alopecia (male pattern baldness), Hair loss in men.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}